Prospective, Single-center, Single-arm Phase 2 Clinical Study on the Efficacy and Safety of Single-agent Neoadjuvant Therapy With Serplulimab in Patients With Non-small Cell Lung Cancer With TPS ≥ 50%.
Latest Information Update: 09 Jan 2024
At a glance
- Drugs Serplulimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Jan 2024 New trial record